---
figid: PMC4591923__nihms422517f1
figlink: /pmc/articles/PMC4591923/figure/F1/
number: Figure 1
caption: 'The signaling pathways of VEGF and HER family members and the current drugs
  that target these proteins in cancer are shown. HER-2 can heterodimerize with any
  of the ligand-activated HER receptors (HER-1, HER-3 or HER-4) and this association
  leads to intracellular signaling via two major pathways, the MAPK pathway and the
  PI3K pathway, leading to proliferation, cell survival, metastasis and angiogenesis.
  On the other hand, VEGF can bind to its main receptor, VEGFR-2 (KDR), and this binding
  causes intracellular phosphorylation of the receptor, thereby stimulating the PI3K
  pathway and stimulating angiogenesis. The signaling pathways can be targeted extracellularly
  using humanized monoclonal antibodies, such as trastuzumab and pertuzumab (HER-2),
  cetuximab (EGF receptor), as well as bevacizumab or VEGF Trap (VEGF), which can
  prevent ligand binding and activation of the receptors or can directly block binding
  of an activated receptor to another. At the intracellular level, small-molecule
  inhibitors, such as sunitinib (VEGF), lapatinib (HER-1 and HER-2) and erlotinib
  (HER-2), can disrupt the phosphorylation sites and directly prevent activation of
  the PI3K or MAPK pathways.P: Phosphate; VEGFR: VEGF receptor.'
pmcid: PMC4591923
papertitle: Peptide vaccines and peptidomimetics targeting HER and VEGF proteins may
  offer a potentially new paradigm in cancer immunotherapy.
reftext: Pravin TP Kaumaya, et al. Future Oncol. ;8(8):961-987.
pmc_ranked_result_index: '13989'
pathway_score: 0.9745668
filename: nihms422517f1.jpg
figtitle: Peptide vaccines and peptidomimetics targeting HER and VEGF proteins may
  offer a potentially new paradigm in cancer immunotherapy
year: ''
organisms: Homo sapiens
ndex: e82d793a-dec1-11ea-99da-0ac135e8bacf
annotations: []
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC4591923__nihms422517f1.html
  '@type': Dataset
  description: 'The signaling pathways of VEGF and HER family members and the current
    drugs that target these proteins in cancer are shown. HER-2 can heterodimerize
    with any of the ligand-activated HER receptors (HER-1, HER-3 or HER-4) and this
    association leads to intracellular signaling via two major pathways, the MAPK
    pathway and the PI3K pathway, leading to proliferation, cell survival, metastasis
    and angiogenesis. On the other hand, VEGF can bind to its main receptor, VEGFR-2
    (KDR), and this binding causes intracellular phosphorylation of the receptor,
    thereby stimulating the PI3K pathway and stimulating angiogenesis. The signaling
    pathways can be targeted extracellularly using humanized monoclonal antibodies,
    such as trastuzumab and pertuzumab (HER-2), cetuximab (EGF receptor), as well
    as bevacizumab or VEGF Trap (VEGF), which can prevent ligand binding and activation
    of the receptors or can directly block binding of an activated receptor to another.
    At the intracellular level, small-molecule inhibitors, such as sunitinib (VEGF),
    lapatinib (HER-1 and HER-2) and erlotinib (HER-2), can disrupt the phosphorylation
    sites and directly prevent activation of the PI3K or MAPK pathways.P: Phosphate;
    VEGFR: VEGF receptor.'
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - ERBB4
  - AKT3
  - AKT2
  - AKT1
  - PIK3CA
  - PIK3CB
  - PIK3CD
  - PIK3R4
  - VEGFC
  - MAP2K4
  - MAP2K3
  - ERBB3
  - MAP2K5
  - MAP2K6
  - MAP2K7
  - KDR
  - PIK3R5
  - PIK3R6
  - EGFR
  - GRB2
  - ERBB2
  - PIK3R3
  - ARAF
  - RAF1
  - BRAF
  - KRAS
  - NRAS
  - MTOR
  - TGFA
  - TRRAP
  - VEGFD
  - PGF
  - VEGFA
  - PIK3CG
  - RALGDS
  - HRAS
  - VEGFB
  - Cancer
  - Lung cancer
genes:
- word: HER-4
  symbol: HER4
  source: hgnc_alias_symbol
  hgnc_symbol: ERBB4
  entrez: '2066'
- word: AKT
  symbol: AKT
  source: bioentities_symbol
  hgnc_symbol: AKT3
  entrez: '10000'
- word: AKT
  symbol: AKT
  source: bioentities_symbol
  hgnc_symbol: AKT2
  entrez: '208'
- word: AKT
  symbol: AKT
  source: bioentities_symbol
  hgnc_symbol: AKT1
  entrez: '207'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3CA
  entrez: '5290'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3CB
  entrez: '5291'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3CD
  entrez: '5293'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3R4
  entrez: '30849'
- word: VEGF
  symbol: VEGF
  source: bioentities_symbol
  hgnc_symbol: VEGFC
  entrez: '7424'
- word: MAPKK
  symbol: MAPKK
  source: bioentities_symbol
  hgnc_symbol: MAP2K4
  entrez: '6416'
- word: MAPKK
  symbol: MAPKK
  source: bioentities_symbol
  hgnc_symbol: MAP2K3
  entrez: '5606'
- word: HER-3
  symbol: HER3
  source: hgnc_alias_symbol
  hgnc_symbol: ERBB3
  entrez: '2065'
- word: MAPKK
  symbol: MAPKK
  source: bioentities_symbol
  hgnc_symbol: MAP2K5
  entrez: '5607'
- word: MAPKK
  symbol: MAPKK
  source: bioentities_symbol
  hgnc_symbol: MAP2K6
  entrez: '5608'
- word: MAPKK
  symbol: MAPKK
  source: bioentities_symbol
  hgnc_symbol: MAP2K7
  entrez: '5609'
- word: VEGFR-2/KDR
  symbol: KDR
  source: hgnc_symbol
  hgnc_symbol: KDR
  entrez: '3791'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3R5
  entrez: '23533'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3R6
  entrez: '146850'
- word: EGFR
  symbol: EGFR
  source: hgnc_symbol
  hgnc_symbol: EGFR
  entrez: '1956'
- word: Grb2
  symbol: GRB2
  source: hgnc_symbol
  hgnc_symbol: GRB2
  entrez: '2885'
- word: HER2
  symbol: HER-2
  source: hgnc_alias_symbol
  hgnc_symbol: ERBB2
  entrez: '2064'
- word: HER-2
  symbol: HER-2
  source: hgnc_alias_symbol
  hgnc_symbol: ERBB2
  entrez: '2064'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3R3
  entrez: '8503'
- word: Raf
  symbol: RAF
  source: bioentities_symbol
  hgnc_symbol: ARAF
  entrez: '369'
- word: Raf
  symbol: RAF
  source: bioentities_symbol
  hgnc_symbol: RAF1
  entrez: '5894'
- word: Raf
  symbol: RAF
  source: bioentities_symbol
  hgnc_symbol: BRAF
  entrez: '673'
- word: Ras
  symbol: RAS
  source: bioentities_symbol
  hgnc_symbol: KRAS
  entrez: '3845'
- word: Ras
  symbol: RAS
  source: bioentities_symbol
  hgnc_symbol: NRAS
  entrez: '4893'
- word: MTOR
  symbol: MTOR
  source: hgnc_symbol
  hgnc_symbol: MTOR
  entrez: '2475'
- word: TGF-a
  symbol: TGFA
  source: hgnc_symbol
  hgnc_symbol: TGFA
  entrez: '7039'
- word: Trap
  symbol: TR-AP
  source: hgnc_alias_symbol
  hgnc_symbol: TRRAP
  entrez: '8295'
- word: VEGF
  symbol: VEGF
  source: bioentities_symbol
  hgnc_symbol: VEGFD
  entrez: '2277'
- word: VEGF
  symbol: VEGF
  source: bioentities_symbol
  hgnc_symbol: PGF
  entrez: '5228'
- word: VEGF
  symbol: VEGF
  source: bioentities_symbol
  hgnc_symbol: VEGFA
  entrez: '7422'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3CG
  entrez: '5294'
- word: RGF
  symbol: RGF
  source: hgnc_alias_symbol
  hgnc_symbol: RALGDS
  entrez: '5900'
- word: VEGF-A
  symbol: VEGF-A
  source: hgnc_alias_symbol
  hgnc_symbol: VEGFA
  entrez: '7422'
- word: VEGFR-2/KDR
  symbol: VEGFR2
  source: hgnc_alias_symbol
  hgnc_symbol: KDR
  entrez: '3791'
- word: Ras
  symbol: RAS
  source: bioentities_symbol
  hgnc_symbol: HRAS
  entrez: '3265'
- word: VEGF
  symbol: VEGF
  source: bioentities_symbol
  hgnc_symbol: VEGFB
  entrez: '7423'
chemicals: []
diseases:
- word: Cancer
  source: ''
  identifier: ''
- word: Lung cancer
  source: ''
  identifier: ''
---
